Skip to main content

Dr. Stella Lee

ENT (Otolaryngology) (Otolaryngology Physician)

  • Medicare participating

At a glance

Years since graduation
21
In the NPI registry since
2007
Medicare patients seen, 2024
232

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Medical school: R Franklin University of Med & Sci/Chicago Medical School
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Otolaryngology Physician primary
    PA license MD442225

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: ENT (Otolaryngology) per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
232
Services billed
878
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Diagnostic exam of nasal passages using an endoscope227148
Established patient office or other outpatient visit, 20-29 minutes9658
Established patient office or other outpatient visit, 30-39 minutes6153
New patient office or other outpatient visit, 45-59 minutes5555
New patient office or other outpatient visit, 30-44 minutes3030
Biopsy or removal of nasal polyp or tissue using an endoscope1713

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 7 companies reported 68 payments worth $132,209 in total to this clinician.

By company
Genzyme Corporation$73,417
AstraZeneca Pharmaceuticals LP$37,108
GlaxoSmithKline, LLC.$12,809
Insmed, Inc.$4,897
Regeneron Pharmaceuticals, Inc.$3,536
Aerin Medical Inc.$368
Medtronic, Inc.$73.72
By type
Compensation for services other than consulting (speaking, faculty)$59,229
Consulting Fee$51,741
Travel and Lodging$20,173
Food and Beverage$1,066

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 6, 2025Genzyme Corporation
Apr 6, 2025
Compensation for services other than consulting (speaking, faculty)
DUPIXENT · Immunology
$33,744
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Consulting Fee
DUPIXENT · Immunology
$12,744
May 21, 2025AstraZeneca Pharmaceuticals LP
May 21, 2025
Compensation for services other than consulting (speaking, faculty)
TEZSPIRE · Respiratory
Company’s descriptionSpeaker Fee
$5,200
Sep 9, 2025AstraZeneca Pharmaceuticals LP
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
TEZSPIRE · Respiratory
Company’s descriptionSpeaker Fee
$5,200
Mar 2, 2025Genzyme Corporation
Mar 2, 2025
Compensation for services other than consulting (speaking, faculty)$5,185
Apr 6, 2025Genzyme Corporation
Apr 6, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Lisboa, Portugal · in-kind
$4,964
Dec 19, 2025GlaxoSmithKline, LLC.
Dec 19, 2025
Compensation for services other than consulting (speaking, faculty)$4,800
Apr 4, 2025Insmed, Inc.
Apr 4, 2025
Consulting Fee$4,458
Jun 21, 2025Genzyme Corporation
Jun 21, 2025
Consulting Fee
DUPIXENT · Immunology
$3,800
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind
$3,600
All 52 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 19, 2025GlaxoSmithKline, LLC.
Dec 19, 2025
Compensation for services other than consulting (speaking, faculty)$4,800
Dec 19, 2025GlaxoSmithKline, LLC.
Dec 19, 2025
Compensation for services other than consulting (speaking, faculty)$2,400
Dec 4, 2025GlaxoSmithKline, LLC.
Dec 4, 2025
Travel and Lodging
travel to Oak Creek, WI · in-kind
$1,055
Dec 4, 2025GlaxoSmithKline, LLC.
Dec 4, 2025
Travel and Lodging
travel to Milwaukee, WI · in-kind
$670
Dec 4, 2025GlaxoSmithKline, LLC.
Dec 4, 2025
Travel and Lodging
travel to Oak Creek, WI · in-kind
$283
Nov 20, 2025GlaxoSmithKline, LLC.
Nov 20, 2025
Compensation for services other than consulting (speaking, faculty)$1,200
Oct 27, 2025AstraZeneca Pharmaceuticals LP
Oct 27, 2025
Consulting Fee
TEZSPIRE · Respiratory
Company’s descriptionResearch Related Service
$3,575
Oct 9, 2025AstraZeneca Pharmaceuticals LP
Oct 9, 2025
Consulting Fee
TEZSPIRE · Respiratory
Company’s descriptionResearch Related Service
$1,625
Oct 2, 2025Genzyme Corporation
Oct 2, 2025
Compensation for services other than consulting (speaking, faculty)
DUPIXENT · Immunology · in-kind
Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total.
$500
Oct 2, 2025Genzyme Corporation
Oct 2, 2025
Compensation for services other than consulting (speaking, faculty)
DUPIXENT · Immunology · in-kind
Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total.
$250
Sep 15, 2025GlaxoSmithKline, LLC.
Sep 15, 2025
Consulting Fee
NUCALA · IMMUNOLOGY
$2,400
Sep 9, 2025AstraZeneca Pharmaceuticals LP
Sep 9, 2025
Compensation for services other than consulting (speaking, faculty)
TEZSPIRE · Respiratory
Company’s descriptionSpeaker Fee
$5,200
Sep 7, 2025AstraZeneca Pharmaceuticals LP
Sep 7, 2025
Travel and Lodging
TEZSPIRE · Respiratory · travel to Palm Beach, FL · in-kind
Company’s descriptionSpeaker Expenses
$405
Sep 7, 2025AstraZeneca Pharmaceuticals LP
Sep 7, 2025
Travel and Lodging
TEZSPIRE · Respiratory · travel to Palm Beach, FL · in-kind
Company’s descriptionSpeaker Expenses
$257
Sep 7, 2025AstraZeneca Pharmaceuticals LP
Sep 7, 2025
Travel and Lodging
TEZSPIRE · Respiratory · travel to Palm Beach, FL · in-kind
Company’s descriptionSpeaker Expenses
$210
Sep 5, 2025AstraZeneca Pharmaceuticals LP
Sep 5, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$650
Jul 23, 2025AstraZeneca Pharmaceuticals LP
Jul 23, 2025
Consulting Fee
TEZSPIRE · Respiratory
$2,925
Jul 10, 2025AstraZeneca Pharmaceuticals LP
Jul 10, 2025
Consulting Fee
TEZSPIRE · Respiratory
Company’s descriptionResearch Related Service
$2,925
Jul 3, 2025AstraZeneca Pharmaceuticals LP
Jul 3, 2025
Consulting Fee$3,250
Jun 21, 2025Genzyme Corporation
Jun 21, 2025
Consulting Fee
DUPIXENT · Immunology
$3,800
Jun 21, 2025Genzyme Corporation
Jun 21, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind
$3,600
Jun 21, 2025Genzyme Corporation
Jun 21, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary
$226
Jun 21, 2025Genzyme Corporation
Jun 21, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind
$196
Jun 21, 2025Genzyme Corporation
Jun 21, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind
$98.69
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Consulting Fee
DUPIXENT · Immunology
$12,744
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind
$3,600
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Consulting Fee$1,728
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind
$196
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary
$137
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind
$118
Jun 20, 2025Genzyme Corporation
Jun 20, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Budapest, Hungary
$17.25
May 21, 2025AstraZeneca Pharmaceuticals LP
May 21, 2025
Compensation for services other than consulting (speaking, faculty)
TEZSPIRE · Respiratory
Company’s descriptionSpeaker Fee
$5,200
May 17, 2025AstraZeneca Pharmaceuticals LP
May 17, 2025
Travel and Lodging
TEZSPIRE · Respiratory · travel to New Orleans, LA · in-kind
Company’s descriptionSpeaker Expenses
$1,277
May 17, 2025AstraZeneca Pharmaceuticals LP
May 17, 2025
Travel and Lodging
TEZSPIRE · Respiratory · travel to New Orleans, LA · in-kind
Company’s descriptionSpeaker Expenses
$983
May 17, 2025AstraZeneca Pharmaceuticals LP
May 17, 2025
Travel and Lodging
TEZSPIRE · Respiratory · travel to New Orleans, LA · in-kind
Company’s descriptionSpeaker Expenses
$391
May 2, 2025Regeneron Pharmaceuticals, Inc.
May 2, 2025
Consulting Fee
DUPIXENT · IMMUNOLOGY AND INFLAMMATION
$416
Apr 18, 2025Regeneron Pharmaceuticals, Inc.
Apr 18, 2025
Consulting Fee
DUPIXENT · IMMUNOLOGY AND INFLAMMATION
$2,080
Apr 18, 2025Regeneron Pharmaceuticals, Inc.
Apr 18, 2025
Consulting Fee
DUPIXENT · IMMUNOLOGY AND INFLAMMATION
$1,040
Apr 11, 2025AstraZeneca Pharmaceuticals LP
Apr 11, 2025
Consulting Fee
TEZSPIRE · Respiratory
Company’s descriptionResearch Related Service
$975
Apr 6, 2025Genzyme Corporation
Apr 6, 2025
Compensation for services other than consulting (speaking, faculty)
DUPIXENT · Immunology
$33,744
Apr 6, 2025Genzyme Corporation
Apr 6, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Lisboa, Portugal · in-kind
$4,964
Apr 6, 2025Genzyme Corporation
Apr 6, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Lisboa, Portugal · in-kind
$501
Apr 6, 2025Genzyme Corporation
Apr 6, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Lisboa, Portugal · in-kind
$369
Apr 6, 2025Genzyme Corporation
Apr 6, 2025
Travel and Lodging
DUPIXENT · Immunology · travel to Lisboa, Portugal
$241
Apr 4, 2025Insmed, Inc.
Apr 4, 2025
Consulting Fee$4,458
Mar 2, 2025Genzyme Corporation
Mar 2, 2025
Compensation for services other than consulting (speaking, faculty)$5,185
Feb 28, 2025Genzyme Corporation
Feb 28, 2025
Compensation for services other than consulting (speaking, faculty)
DUPIXENT · Immunology · in-kind
Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total.
$500
Feb 28, 2025Insmed, Inc.
Feb 28, 2025
Travel and Lodging
travel to San Diego, CA · in-kind
$375
Feb 28, 2025Genzyme Corporation
Feb 28, 2025
Compensation for services other than consulting (speaking, faculty)
DUPIXENT · Immunology · in-kind
Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total.
$250
Feb 6, 2025AstraZeneca Pharmaceuticals LP
Feb 6, 2025
Consulting Fee
TEZSPIRE · Respiratory
$1,950
Jan 10, 2025AstraZeneca Pharmaceuticals LP
Jan 10, 2025
Consulting Fee
FASENRA · Respiratory
$2,600
Jan 10, 2025AstraZeneca Pharmaceuticals LP
Jan 10, 2025
Consulting Fee
TEZSPIRE · Respiratory
$2,600

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $110,909 in research payments for these studies, mostly to the institutions running them.

  • A Multicentre Single-Arm Phase 3b Study to Assess Changes in Symptoms in Adult Participants with Chronic Rhinosinusitis with Nasal Polyposis Initiating Treatment with Tezepelumab (ESSENCE)
    AstraZeneca Pharmaceuticals LP
  • A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
    Sanofi US Services Inc. · Completed · NCT06454240
  • A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT
    AstraZeneca Pharmaceuticals LP
  • A Multicentre Single-Arm Phase 3b Study to Assess Changes in Symptoms in Adult Participants with Chronic Rhinosinusitis with Nasal Polyposis Initiating Treatment with Tezepelumab (ESSENCE)
    AstraZeneca UK Limited

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other ENT (Otolaryngology) clinicians in Pittsburgh

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 6, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1851573893. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.